CONFIDENTIALITY AGREEMENTConfidentiality Agreement • April 26th, 2022 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This agreement (this “Agreement”), dated February 18, 2022 (the “Effective Date”), shall serve to set forth the terms and conditions between Antares Pharma, Inc. (“Antares”), a Delaware corporation having its principal place of business at 100 Princeton South Corporate Center, Suite 300 Ewing, New Jersey 08628 USA, and Halozyme Therapeutics, Inc. (“Company”), a Delaware corporation having its principal place of business at 11388 Sorrento Valley Road, San Diego California 92121 (each, a “Party,” and collectively, the “Parties”), under which each Party may disclose and/or deliver to the other Party, either directly or indirectly through a Representative (as defined below), proprietary and confidential, oral and written information relating to its business and operations (such Party when disclosing such information being the “Disclosing Party” and such Party when receiving such information being the “Receiving Party”) solely for each Party’s consideration of a possible negotiated merger o
Ewing, New Jersey 08628 Re: Exclusivity AgreementExclusivity Agreement • April 26th, 2022 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Reference is made to our discussions regarding a possible negotiated acquisition (the “Proposed Transaction”) of all of the issued and outstanding shares of common stock of Antares Pharma, Inc. (the “Company”) by Halozyme Therapeutics, Inc. (“Halozyme”). In order to facilitate and expedite continued discussions between the Company and Halozyme with respect to the Proposed Transaction, and to induce Halozyme to continue to devote substantial time and effort to the evaluation and documentation of the Proposed Transaction, the parties hereto hereby agree as set forth below (the “Exclusivity Agreement”).
